Nomura Holdings Inc vs Tilray Brands Inc — how do they compare? Nomura Holdings Inc trades at $9.57 (market cap $27.55B), while Tilray Brands Inc trades at $3.5 (market cap $530.54M). The key difference: Nomura Holdings Inc is far larger — about 51.9× Tilray Brands Inc's market cap, and Nomura Holdings Inc pays a 3.4% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nomura Holdings Inc for 55 Days and Tilray Brands Inc for 31 Days on average.
| NMR | TLRY | |
|---|---|---|
Market Cap | $27.55B | $530.54M |
Volume | 782,470 | 9,099,075 |
Sector | Financials | Health |
52-Week High | $10.86 | $21.00 |
52-Week Low | $6.73 | $3.57 |
Typical Hold Time | 55 Days | 31 Days |
Enterprise Value | $38.54T | $684.46M |
Dividend Yield | 3.4% | — |
Signals from Pluang's Aura AI — not financial advice
Nomura Holdings (NMR) trades at $9.57, showing modest daily gains of 0.42%. The stock presents a mixed technical picture with bearish moving averages but oversold RSI readings. Fundamentally, NMR demonstrates strong profitability with 20.4% net margins and attractive valuation metrics including a P/E of 11.33 and P/B of 1.15. Recent earnings show volatility with two misses and one beat in the last four quarters. The company maintains robust revenue growth, reaching $1.66 trillion in 2025 with expanding profit margins.
NMR offers value investment appeal with reasonable valuations and solid profitability, though technical weakness and inconsistent earnings performance present near-term challenges. The stock's current oversold condition combined with strong fundamental metrics suggests potential for recovery, but investors should monitor earnings consistency and debt levels that have been trending upward. Analyst sentiment remains cautiously optimistic with a buy rating consensus despite recent technical pressure.
TLRY trades at $3.465, down 6.73% on the day and near 52-week lows, reflecting persistent bearish sentiment. The stock shows weak technical momentum with oversold RSI readings but faces fundamental challenges including consecutive quarterly earnings misses, negative profit margins, and declining revenue growth. Recent news highlights the company's struggles with profitability despite record annual revenue, with shares down over 50% year-to-date as investors question the cannabis company's path to sustainable growth.
TLRY presents a high-risk opportunity with significant downside protection from its low P/B ratio of 0.33, but requires substantial operational improvement to justify investment. The bullish case hinges on potential marijuana reform catalysts and BrewDog integration progress, while risks include ongoing losses, competitive pressures, and execution challenges in a volatile regulatory environment.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →